Mylan Prepares To Launch Canada's First Trastuzumab Within Weeks
By the end of June, Mylan expects to have launched in Canada the Ogivri trastuzumab 150mg and 440mg vials for which it has just received regulatory approval.
You may also be interested in...
Mylan and Biocon have introduced the second biosimilar pegfilgrastim rival to Neulasta in Canada with the launch of their Fulphila version.
Celltrion and Teva have now received a Health Canada approval for their Herzuma trastuzumab biosimilar. However, notices of compliance have already been granted for rival biosimilars from Mylan and Pfizer.
India’s Biocon reported first-quarter net profit that soared by more than 70% and said it was confident of a “very successful” US trastuzumab launch, despite rival Amgen stealing a march by commercializing its own biosimilar first in the world’s largest drug market.